Immunomagnetic bone marrow (BM) and peripheral blood progenitor cell (PBPC) purging in follicular lymphoma (FL)

Bone Marrow Transplantation

Volumn 23, Issue 6, 1999, Pages 579-587

  Martin Henao G A ^a,c   Picon M ^a   Limon A ^a   Carmona, M ^a   Amill, B ^a   Azqueta, C ^a   Lopez R ^b   Gonzalez Barca E ^c   Granena A ^c   Bruneit, S ^b   Garcia J ^a  

^a Institut de Recerca Oncologica   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c HOSPITAL DURAN I REYNALS   (Spain)

Author keywords

Follicular lymphoma; Immunomagnetic purging

Indexed keywords

CD34 ANTIGEN; MONOCLONAL ANTIBODY; PROTEIN BCL 2;

ADULT; ARTICLE; B CELL LYMPHOMA; BONE MARROW PURGING; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; FEMALE; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; PERIPHERAL BLOOD STEM CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TARGET CELL;

EID: 2542507904     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701612     Document Type: Article

References (35)

1. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapse of chemotherapy-sensitive non-Hodgkin's lymphoma. New Engl J Med 1995; 333: 1540-1545.
2. Rohatiner AZ, Johnson PW, Price CG et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 1994; 12: 1177-1184.
3. Freedman AS, Gribben JG, Neuberg D et al. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996; 88: 2780-2786.
4. Armitage JO. Bone marrow transplantation for indolent lymphomas. Semin Oncol 1993; 20 (Suppl. 5): 136-142.
5. Stein RS, Ultmann JE, Byrne GA et al. Bone marrow involvement in non-Hodgkin's lymphomas: implication for staging and therapy. Cancer 1976; 37: 629-636.
6. Negrin RS, Pesendo J. Detection of tumor cells in purged bone marrow and peripheral-blood mononuclear cells by polymerase chain reaction amplification of bcl-2 translocation. J Clin Oncol 1994; 12: 1021-1027.
7. Benjamin D, Magrath IT, Douglass EC, Corash LM. Derivation of lymphoma cells lines from microscopically normal bone marrow in patients with undifferentiated lymphoma: evidence of occult bone marrow involvement. Blood 1983; 61: 1017-1019.
8. Yuan R, Dowling P, Zucca E et al. Detection of bcl-2/JH rearrangement in follicular and diffuse lymphoma: concordant results of peripheral blood and bone marrow analysis at diagnosis. Br J Cancer 1993; 67: 922-925.
9. Corradini P, Astolfi M, Cherasco C et al. Molecular monitoring of minimal residual disease in follicular and mantle cells non-Hodgin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. Blood 1997; 2: 724-731.
10. Léonard BM, Hétu F, Busque L et al. Lymphoma cell burden in progenitor cell grafts measured by competitive polymerase chain reaction: less than one log difference between bone marrow and peripheral blood source. Blood 1998; 91: 331-339.
11. Brenner MK, Rill DR, Moen RC et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341: 85-86.
12. Deisseroth A, Zu Z, Claxton D et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994; 83: 3068-3076.
13. Sharp JG, Joshi SS, Armitage JO et al. Significance of detection of occult non-Hodgkin's lymphoma in histologically uninvolved bone marrow by a culture technique. Blood 1992; 79: 1074-1080.
14. Gribben JG, Freedman AS, Neuberg D et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. New Engl J Med 1991; 325: 1525-1533.
15. Hurd DD, LeBien TW, Lasky LC et al. Autologous bone marrow transplantation in non-Hodgkin's lymphoma: monoclonal antibodies plus complement for ex vivo marrow treatment. Am J Med 1988; 85: 829-834.
16. Uckun FM, Gajl-Peczalska K, Meyers DE et al. Marrow purging in autologous transplantation for T-lineage acute lymphoblastic leukemia; efficacy of ex vivo treatment with immunotoxins and 4-hydroperoxycyclophosphamide against fresh leukemic marrow progenitor cells. Blood 1987; 69: 361-366.
17. Canals C, Torrico C, Picón M et al. Immunomagnetic bone marrow purging in children with acute lymphoblastic leukemia. J Hematother 1997; 6: 261-268.
18. Treleaven JG, Gibson FM, Ugelstad J et al. Removal of neuroblastoma cells from bone marrow with monoclonal antibodies conjugated to magnetic microspheres. Lancet 1984; 14: 70-73.
19. Gribben JG, Saporito L, Barber M et al. Bone marrow of non-Hodgkin's lymphoma patients with a bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion. Blood 1992; 80: 1083-1089.
20. Shimazaki C, Wisniewski D, Scheinberg DA et al. Elimination of myeloma cells from bone marrow by using monoclonal antibodies and magnetic immunobeads. Blood 1988; 72: 1248-1254.
21. Shpall EJ, Bast RC, Joines WT et al. Immunomagnetic purging of breast cancer from bone marrow for autologous transplantation. Bone Marrow Transplant 1991; 7: 145-151.
22. Kvalheim G, Sorensen O, Fodstad O et al. Immunomagnetic removal of B-lymphoma cells from human bone marrow: a procedure for clinical use. Bone Marrow Transplant 1988; 3: 31-41.
23. Kvalheim G, Wang MY, Pharo A et al. Purging of tumor cells from leukapheresis products: experimental and clinical aspects. J Hematother 1996; 5: 427-436.
24. García J, Punti C, Picon M et al. Bone marrow purging in acute lymphoblastic leukemia: biological and clinical features. J Hematother 1994; 3: 203-211.
25. Gilmore MJML, Prentice HG, Corringham RE et al. A technique for the concentration of nucleated bone marrow cells for in vitro manipulation or cryopreservation using the IBM 2991 Blood Cell Processor. Vox Sang 1983; 45: 294-302.
26. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: a Laboratory Manual. Cold Spring Harbor Laboratory: Cold Spring Harbor, NY, 1989.
27. Drexler K, Jobs G, du Moulin A et al. PCR monitoring of minimal residual disease by quantitative PCR specific for t(14;18) chromosomal translocation in follicular non-Hodgkin's lymphoma. Bone Marrow Transplant 1994; 14: 213 (Abstr. 476).
28. Johnson PW, Price CG, Smith T et al. Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma. J Clin Oncol 1994; 12: 798-805.
29. Haas R, Moos M, Karcher A et al. Sequential high-dose therapy with peripheral blood progenitor cell support in low-grade non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 1685-1692.
30. Brice P, Marolleau JP, Pautier P et al. Hematologic recovery and survival of lymphoma patients after autologous stem-cell transplantation: comparison of bone marrow and peripheral blood progenitor cells. Leuk Lymphoma 1996; 22: 449-456.
31. Schmitz N, Linch DC, Dreger P et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353-357.
32. + cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 1998; 91: 3148-3155.
33. Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547-2555.
34. Kessinger A, Armitage JO. The evolving role of autologous peripheral stem cell transplantation following high-dose therapy for malignancies. Blood 1991; 77: 211-213.
35. Woronoff-Lemsi MC, Arveux P, Limat S et al. Cost comparative study of autologous peripheral blood progenitors cells (PBPC) and bone marrow (ABM) transplantation for non-Hodgkin's lymphoma patients. Bone Marrow Transplant 1997; 20: 975-982.